KR100340981B1 - Hydrophilic Polyurethane Foam Dressing and Method of Making the Same - Google Patents
Hydrophilic Polyurethane Foam Dressing and Method of Making the Same Download PDFInfo
- Publication number
- KR100340981B1 KR100340981B1 KR1019990026417A KR19990026417A KR100340981B1 KR 100340981 B1 KR100340981 B1 KR 100340981B1 KR 1019990026417 A KR1019990026417 A KR 1019990026417A KR 19990026417 A KR19990026417 A KR 19990026417A KR 100340981 B1 KR100340981 B1 KR 100340981B1
- Authority
- KR
- South Korea
- Prior art keywords
- polyurethane foam
- dressing material
- foam dressing
- hydrophilic polyurethane
- weight
- Prior art date
Links
- 229920005830 Polyurethane Foam Polymers 0.000 title claims abstract description 52
- 239000011496 polyurethane foam Substances 0.000 title claims abstract description 52
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 61
- 206010052428 Wound Diseases 0.000 claims abstract description 28
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 28
- 229920001730 Moisture cure polyurethane Polymers 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000011148 porous material Substances 0.000 claims abstract description 11
- 230000029663 wound healing Effects 0.000 claims abstract description 11
- 229920005862 polyol Polymers 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract description 9
- 150000003077 polyols Chemical class 0.000 claims abstract description 9
- 239000004604 Blowing Agent Substances 0.000 claims abstract description 8
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 8
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 7
- 125000005442 diisocyanate group Chemical group 0.000 claims abstract description 7
- 229920000570 polyether Polymers 0.000 claims abstract description 7
- 230000000996 additive effect Effects 0.000 claims abstract description 6
- 239000010409 thin film Substances 0.000 claims abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 238000005187 foaming Methods 0.000 claims abstract 2
- 230000003020 moisturizing effect Effects 0.000 claims abstract 2
- 238000000465 moulding Methods 0.000 claims abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 230000000704 physical effect Effects 0.000 claims description 8
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 7
- 229920005604 random copolymer Polymers 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 3
- 239000005058 Isophorone diisocyanate Substances 0.000 claims description 3
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920005682 EO-PO block copolymer Polymers 0.000 claims description 2
- 229920000569 Gum karaya Polymers 0.000 claims description 2
- 241000934878 Sterculia Species 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical group F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 235000010494 karaya gum Nutrition 0.000 claims description 2
- 239000000231 karaya gum Substances 0.000 claims description 2
- 229940039371 karaya gum Drugs 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- -1 diisocyanate compound Chemical class 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000035699 permeability Effects 0.000 abstract description 12
- 239000006260 foam Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000011248 coating agent Substances 0.000 abstract description 3
- 238000000576 coating method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- 210000000416 exudates and transudate Anatomy 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010048629 Wound secretion Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008952 bacterial invasion Effects 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VGHSXKTVMPXHNG-UHFFFAOYSA-N 1,3-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC(N=C=O)=C1 VGHSXKTVMPXHNG-UHFFFAOYSA-N 0.000 description 1
- SBJCUZQNHOLYMD-UHFFFAOYSA-N 1,5-Naphthalene diisocyanate Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1N=C=O SBJCUZQNHOLYMD-UHFFFAOYSA-N 0.000 description 1
- VZXPHDGHQXLXJC-UHFFFAOYSA-N 1,6-diisocyanato-5,6-dimethylheptane Chemical compound O=C=NC(C)(C)C(C)CCCCN=C=O VZXPHDGHQXLXJC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GWGWXYUPRTXVSY-UHFFFAOYSA-N N=C=O.N=C=O.CC1=CC=C(C)C=C1 Chemical compound N=C=O.N=C=O.CC1=CC=C(C)C=C1 GWGWXYUPRTXVSY-UHFFFAOYSA-N 0.000 description 1
- UQBRAHLFLCMLBA-UHFFFAOYSA-N N=C=O.N=C=O.CC1=CC=CC(C)=C1 Chemical compound N=C=O.N=C=O.CC1=CC=CC(C)=C1 UQBRAHLFLCMLBA-UHFFFAOYSA-N 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- RHJVJSBJAPQUOS-UHFFFAOYSA-N [S].[Ag].C1=CC=NN=C1 Chemical compound [S].[Ag].C1=CC=NN=C1 RHJVJSBJAPQUOS-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000002666 chemical blowing agent Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010097 foam moulding Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- XJRAOMZCVTUHFI-UHFFFAOYSA-N isocyanic acid;methane Chemical compound C.N=C=O.N=C=O XJRAOMZCVTUHFI-UHFFFAOYSA-N 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AYLRODJJLADBOB-QMMMGPOBSA-N methyl (2s)-2,6-diisocyanatohexanoate Chemical compound COC(=O)[C@@H](N=C=O)CCCCN=C=O AYLRODJJLADBOB-QMMMGPOBSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 229940117969 neopentyl glycol Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QXJQHYBHAIHNGG-UHFFFAOYSA-N trimethylolethane Chemical compound OCC(C)(CO)CO QXJQHYBHAIHNGG-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/48—Surfactants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing & Machinery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
본 발명은 폐쇄성 창상 피복재로서 사용하는 친수성 폴리우레탄 폼 드레싱재 및 그 제조 방법에 관한 것이다. 기존의 친수성 폴리우레탄 폼 드레싱재의 단점인 저투습도에 따른 지속적 삼출물 흡수력 부족, 창면 부착, 복잡한 가공 공정에 따른 고가격의 문제점을 해결하기 위한 것으로서 단순한 가공 공정으로 고투습도와 창면 비부착 특성을 갖는 친수성 폴리우레탄 폼 드레싱재를 제조하는 것을 목적으로 한다. 본 발명에 따르면, 디이소시아네이트와 폴리에테르폴리올을 반응하여 합성한 폴리우레탄 프레폴리머 40∼79중량%; 발포제 15∼45중량%; 가교제 5∼35중량%와 계면활성제, 보습제, 항균제 등의 첨가제 1∼15중량%를 혼합하여 일정한 형태의 몰드에 주입하고 발포, 성형하여 제조하는 친수성 폴리우레탄 폼 드레싱재 및 그 제조 방법이 제공된다. 본 발명에 따라 제조되는 친수성 폴리우레탄 폼 드레싱재는, 구조가 직경 3∼60㎛의 포아(pore)를 갖는 박필름의 표피층과 직경 50∼500㎛의 오픈 셀(open cell)을 갖는 내부층으로 이루어져 있고, 탁월한 투습도와 삼출물 흡수력을 나타내고 창면 부착을 방지하며, 창상치유 효과가 우수하고 저가격으로 광범위 창상에 적용할 수 있다.The present invention relates to a hydrophilic polyurethane foam dressing material for use as a closed wound coating material and a method for producing the same. It is a hydrophilic poly with high moisture permeability and window non-adhesive property with simple processing process to solve the problems of lack of continuous exudation ability, window attachment, and complicated processing process due to low moisture permeability, which is a disadvantage of the conventional hydrophilic polyurethane foam dressing material. It aims at manufacturing a urethane foam dressing material. According to the present invention, 40 to 79% by weight of a polyurethane prepolymer synthesized by reacting a diisocyanate with a polyether polyol; 15 to 45% by weight of blowing agent; Provided are a hydrophilic polyurethane foam dressing material which is prepared by mixing 5 to 35% by weight of a crosslinking agent with 1 to 15% by weight of an additive such as a surfactant, a moisturizing agent, and an antibacterial agent, and then foaming and molding a mold. . The hydrophilic polyurethane foam dressing material produced according to the present invention comprises a skin layer of a thin film having a pore having a diameter of 3 to 60 µm and an inner layer having an open cell having a diameter of 50 to 500 µm. It has excellent water vapor permeability and exudant absorption, prevents adhesion of window surface, and has excellent wound healing effect and can be applied to a wide range of wounds at low cost.
Description
본 발명은 폐쇄성 창상 피복재로서 사용하는 친수성 폴리우레탄 폼 드레싱재 및 그 제조 방법에 관한 것으로서, 좀 더 구체적으로는 이소시아네이트 말단기를 갖는 폴리우레탄 프레폴리머와 발포제, 가교제 및 첨가제를 일정비율로 혼합, 교반하고 일정 형상의 몰드에 주입하여 발포, 성형하는 친수성 폴리우레탄 폼 드레싱재의 제조 방법에 관한 것으로, 이와 같은 폼 드레싱재는 그 구조가 직경 3∼60㎛ 포아(pore)를 갖는 표피층과 직경 50∼500㎛의 오픈 셀(open cell)를 갖는 내부층으로 이루어져 있고, 계면활성제, 보습제, 상처치유 촉진제, 항균제 등을 포함하고 있는 폐쇄성 폼 드레싱재의 제조 방법에 관한 것이다.The present invention relates to a hydrophilic polyurethane foam dressing material for use as a closed wound coating material and a method for producing the same, and more specifically, to mixing and stirring a polyurethane prepolymer having an isocyanate end group, a blowing agent, a crosslinking agent, and an additive at a predetermined ratio. The present invention relates to a method for producing a hydrophilic polyurethane foam dressing material which is injected into a mold of a predetermined shape and foamed and molded. Such a foam dressing material has a skin layer having a pore of 3 to 60 µm in diameter and a diameter of 50 to 500 µm. It relates to a method for producing a closed foam dressing material consisting of an inner layer having an open cell, and containing a surfactant, a humectant, a wound healing accelerator, an antibacterial agent and the like.
피부란 인체를 외부 자극으로부터 보호하며 수분의 손실을 막아주고 체온 조절, 세균 침입 방지 등 중요한 생명보호 기능을 수행하는 장기의 하나로서 피부가 화상이나 각종 외상에 의해서 결손이 일어나게 되면 그 보호작용이 상실되어 기능의 장애를 초래하게 되고, 수분 손실 등에 따른 여러가지 부작용과 외부로부터의 세균 감염 등을 일으켜 환부의 치료를 어렵게 하거나, 이차적인 기능장애 또는 손상 등과 같은 추가적인 부작용을 초래하게 되어 심한 경우에는 생명연장에도 영향을 주게 된다. 따라서 상처의 치료를 신속하게 하고 이차적인 각종 부작용을 최소화하기 위해서는 적절한 드레싱을 이용한 상처 치료가 필수적이다.Skin is one of the organs that protects the human body from external stimuli, prevents water loss, and performs vital life protection functions such as controlling body temperature and preventing bacterial invasion. This can lead to functional impairment, which can cause various side effects due to water loss and bacterial infections from the outside, making it difficult to treat the affected area, or causing additional side effects such as secondary dysfunction or damage. It will also affect. Therefore, in order to quickly heal wounds and minimize secondary side effects, it is necessary to treat wounds with appropriate dressings.
창상치유에 관여하는 주요 인자를 간단히 설명하면 습윤환경, 감염, 이물·괴사조직, 온도, 산소농도, PH 등을 들수 있다. 그리고 이상적인 드레싱재의 요건은 상처와의 접촉면에서 적당한 습기의 유지 능력, 삼출물의 흡수 능력, 상처에 대한 부착과 제거의 용이성, 외부와의 가스·수증기 전달 능력, 외부로부터의 단열성, 박테리아의 침입에 대한 방어력, 인체에 무독성, 우수한 기계적 물성, 경제성 등을 들 수 있다.Brief descriptions of the major factors involved in wound healing include a wet environment, infection, foreign body and necrotic tissue, temperature, oxygen concentration, and pH. The requirements of the ideal dressing material are the ability to maintain adequate moisture at the contact surface with the wound, the ability to absorb exudates, the ease of attachment and removal to the wound, the ability to transfer gas and water to the outside, the insulation from the outside, and the invasion of bacteria. Defense, non-toxic to human body, excellent mechanical properties, economics and the like.
통상의 거즈형 드레싱재는 상처 분비물의 흡수는 용이하나 박테리아의 감염에 대한 방어기능이 없고 상처를 건조한 상태로 유지시켜 치료를 지연시킬 뿐만 아니라 드레싱재가 상처면에 부착하여 교환시 제거가 용이하지 못한 문제점이 있고 치유 초기 단계에서는 삼출물이 많기 때문에 하루에도 몇번씩 드레싱을 교환해 주어야하는 단점 등이 있다. 현재 거즈형 드레싱재의 문제점을 개선한 다양한 폐쇄성 드레싱재가 개발되어 사용되고 있으나 고가격이고 흡습성의 조절 용이성 및 투습도의 조절 용이성 부족으로 인하여 광범위 창상에 적용되지 못하고 특정한 용도에만 적용되고 있는 실정이다.현재 주로 사용되고 있는 드레싱재의 종류에는 필름형, 하이드로콜로이드형, 하이드로겔형 그리고 소디움알지네이트 등을 사용한 부직포형, 폴리우레탄 폼형 등이 있다. 특히 폴리우레탄 폼형은 흡습성의 조절이 용이하고 제조상의 간편성 때문에 범용성과 광범위 창상 적용 가능성이 있는 소재로써 기대되고 있다.Conventional gauze dressings are easy to absorb the wound secretion, but they do not have a protective function against bacterial infection, keep the wound dry and delay the treatment, and the dressing material adheres to the wound surface and is not easy to remove when exchanged. In the early stages of healing, there is a lot of exudate, so there are disadvantages such as changing dressings several times a day. Currently, various closed dressing materials have been developed and used to improve the problems of the gauze dressing materials, but due to their high price and hygroscopicity and the lack of control of moisture permeability, they are not applied to a wide range of wounds and are only applied to specific applications. Examples of the dressing material include a film type, a hydrocolloid type, a hydrogel type, a nonwoven fabric using sodium alginate, and a polyurethane foam type. In particular, the polyurethane foam type is expected to be a material that can easily control hygroscopicity and is easy to manufacture due to its versatility and wide application of wounds.
친수성 폴리우레탄 폼 드레싱재의 제조 방법으로써 미국특허 제 4,773,409호에서는 one-shot 공정에 의해 폴리에틸렌글리콜, 이소시아네이트, 촉매, 물, 수용성 또는 수팽윤성 고분자를 혼합하여 제조하였고, 미국특허 제 4,860,737와 5,571,529호에서는 W. R. Grace & Co.사의 HYPOL(이소시아네이트 말단기를 갖는 폴리에테르 프레폴리머), 계면활성제, 물을 혼합하여 제조하였다. 그러나 우레탄 반응 촉진을 위한 촉매를 사용함으로써 인체에 유해하고 기계적 물성이 약하며 삼출물 흡수시 폼의 붕괴가 유발되는 단점을 갖고 있다. 또한 표면에 오픈 셀(open cell) 구조에 의한 큰 포아(pore)를 갖음으로써 외부로부터 박테리아의 침입과 상처면에서의 재생세포가 폴리우레탄 폼의 오픈 셀(open cell) 내부에 부착하여 드레싱재의 교환시 환자에게 고통을 유발시킨다는 단점이 있다.이러한 단점을 보완하기 위하여 미국특허 제 5,296,528 및 5,571,529호에서는 친수성 폴리우레탄 폼의 양면에 필름을 라미네이션시켜 드레싱재를 제조하고 있다. 그러나 제조공정이 복잡하여 비교적 고가이고 흡수능력이 부족해 많은 양의 삼출물이 발생하는 상처에는 적용이 곤란하며 투습도가 높지 않기 때문에 흡수 삼출물의 투습 건조에 따른 지속적인 삼출물 흡수가 곤란하다. 또한 폴리우레탄 폼 자체의 물성 즉, 인장강도, 신율, 모듈러스, 흡수도, 셀 사이즈(cell size) 등의 조절이 힘들다는 문제점 등이 있다.As a method for preparing a hydrophilic polyurethane foam dressing material, US Pat. No. 4,773,409 was prepared by mixing polyethylene glycol, isocyanate, catalyst, water, water-soluble or water swellable polymer by one-shot process, and US Pat. Nos. 4,860,737 and 5,571,529. It was prepared by mixing Grace & Co.'s HYPOL (polyether prepolymer having an isocyanate end group), a surfactant, and water. However, by using a catalyst for promoting the urethane reaction has a disadvantage that it is harmful to the human body, weak mechanical properties and foam collapse when absorbing exudates. In addition, by having a large pore by the open cell structure on the surface, bacteria invasion from the outside and regenerated cells on the wound surface adhere to the open cell of the polyurethane foam to exchange the dressing material. There is a drawback to causing pain in the patient. To compensate for this drawback, US Patent Nos. 5,296,528 and 5,571,529 manufacture a dressing material by laminating films on both sides of a hydrophilic polyurethane foam. However, it is difficult to apply to wounds in which a large amount of exudate is generated due to a complicated manufacturing process due to relatively high cost and lack of absorption ability, and it is difficult to continuously absorb exudates due to the moisture-permeable drying of the absorbent exudate. In addition, there is a problem that it is difficult to control the properties of the polyurethane foam itself, that is, tensile strength, elongation, modulus, absorbance, cell size (cell size).
본 발명은 상기와 같은 종래의 폴리우레탄 폼 드레싱재의 문제점인 저흡수성, 저투습성, 상처부착성, 저물성 등을 개선한 것으로서, 1종 이상의 폴리에테르폴리올을 디이소시아네이트와 반응시켜 폴리우레탄 프레폴리머를 합성한 후 발포제, 가교제, 첨가제를 혼합하여 일정 형상의 몰드에 주입하고 발포, 성형함으로써 그 구조가 직경 3∼60㎛의 포아(pore)를 갖는 표피층과 직경 50∼500㎛의 오픈 셀(open cell)을 갖는 내부층으로 이루어지는 친수성 폴리우레탄 폼 드레싱재 및 그 제조 방법을 제공하는데 목적이 있다.본 발명의 다른 목적은 표피층의 얇은 막에 직경 3∼60㎛의 포아(pore)를 형성시키고, 내부층에는 직경 50∼500㎛의 오픈 셀(open cell)을 형성시킴으로써 박테리아의 상처면 침투와 드레싱재의 상처면 부착을 방지할 수 있는 친수성 폴리우레탄 폼 드레싱재 및 그 제조 방법을 제공하려는 것이다.또한, 본 발명은 계면활성제, 보습제, 상처치유 촉진제, 항균제 등의 첨가제를 함유시킴으로써 상처면의 청결 및 재생세포의 성장을 촉진시킬 수 있는 친수성 폴리우레탄 폼 드레싱재 및 그 제조 방법을 제공하려는 것이다.본 발명의 또 다른 목적은 상기 폴리우레탄 프레폴리머를 합성함에 있어 폴리우레탄 프레폴리머의 NCO%와 각종 원료의 첨가량을 조절함으로써 폴리우레탄 폼 자체의 물성 즉, 인장강도, 신율, 모듈러스, 흡수도, 셀 사이즈(cell size) 등을 조절하고, 삼출물이 적은 창상으로부터 많은 창상에 이르기까지 폭넓게 사용 가능한 폴리우레탄 폼 드레싱재 및 그 제조 방법을 제공하려는 것이다.The present invention is to improve the low water absorption, low moisture permeability, wound adhesion, low physical properties and the like problems of the conventional polyurethane foam dressing as described above, by reacting at least one polyether polyol with diisocyanate to make a polyurethane prepolymer After synthesis, the blowing agent, the crosslinking agent, and the additives are mixed and injected into a mold having a predetermined shape, and then foamed and molded to form an epidermal layer having pores having a diameter of 3 to 60 µm and an open cell having a diameter of 50 to 500 µm. It is an object of the present invention to provide a hydrophilic polyurethane foam dressing material consisting of an inner layer having an inner layer) and a method for producing the same. Another object of the present invention is to form pores having a diameter of 3 to 60 µm in a thin film of the epidermal layer, and Hydrophilic polyurethane foam that prevents bacteria from penetrating the wound and adheres to the dressing material by forming an open cell with a diameter of 50 to 500 µm in the layer The present invention also provides a dressing material and a method of manufacturing the same. The present invention also provides a hydrophilic polyurethane foam capable of promoting cleanliness of wounds and growth of regenerated cells by containing additives such as surfactants, humectants, wound healing accelerators, and antibacterial agents. It is another object of the present invention to synthesize the polyurethane prepolymer, and to adjust the NCO% of the polyurethane prepolymer and the amount of various raw materials to synthesize the polyurethane prepolymer. The present invention is to provide a polyurethane foam dressing material and a method of manufacturing the same, which can be used in a wide range of wounds with a small amount of exudates and many wounds while controlling tensile strength, elongation, modulus, absorbency, cell size, and the like.
도1은 본 발명에 따라 제조된 친수성 폴리우레탄 폼 드레싱재의 단면 모식도.1 is a schematic cross-sectional view of a hydrophilic polyurethane foam dressing material prepared according to the present invention.
도2는 본 발명에 따라 제조된 친수성 폴리우레탄 폼 드레싱재의 표면(a)과 단면(b)의 주사전자현미경 사진.*도면의 주요부분에 대한 부호의 설명*1: 표피층 2: 내부층Figure 2 is a scanning electron micrograph of the surface (a) and cross-section (b) of the hydrophilic polyurethane foam dressing material prepared according to the present invention. * Description of the symbols for the main parts of the drawings * 1: Epidermal layer 2: Inner layer
이하 본 발명을 상세히 설명하면 다음과 같다. 본 발명의 폐쇄성 창상 피복재로서 사용되는 친수성 폴리우레탄 폼 드레싱재는 도1 및 도2에 보인 바와 같이 그 구조가 직경 3∼60㎛ 포아(pore)를 갖는 표피층(1)과 직경 50∼500㎛의 오픈(open cell)을 갖는 내부층(2)으로 이루어진 것으로, 이는 1종 이상의 폴리에테르폴리올을 디이소시아네이트와 반응하여 얻어진 폴리우레탄 프레폴리머 40∼79중량%; 발포제 15∼45 중량%; 가교제 5∼35 중량% 및 첨가제 1∼15 중량%를 첨가하여 혼합 교반한 후 몰드에 주입하여 발포, 성형함을 특징으로 한다.Hereinafter, the present invention will be described in detail. The hydrophilic polyurethane foam dressing material used as the closed wound coating material of the present invention has an open skin having a skin layer 1 having a diameter of 3 to 60 µm pores and a diameter of 50 to 500 µm, as shown in FIGS. 1 and 2. consisting of an inner layer 2 having an open cell, 40 to 79% by weight of a polyurethane prepolymer obtained by reacting at least one polyetherpolyol with a diisocyanate; 15 to 45% by weight of blowing agent; 5 to 35% by weight of the crosslinking agent and 1 to 15% by weight of the additive are added, mixed and stirred, and then injected into the mold to foam and mold.
폴리우레탄 프레폴리머 제조에 있어서 디이소시아네이트 1∼3몰에 대해 1종 이상의 폴리에테르폴리올이 0.15∼0.5몰이 투입되며 디이소시아네이트로는 이소포론디이소시아네이트, 2,4-톨루엔디이소시아네이트 및 그 이성질체, 디페닐메탄디이소시아네이트, 헥사메틸렌디이소시아네이트, 라이신디이소시아네이트, 트리메틸헥사메틸렌디이소시아네이트, 2,2-비스-4′-프로판이소시아네이트, 6-이소프로필-1,3-페닐디이소시아네이트, 비스(2-이소시아네이트에틸)-퓨마레이트, 3,3′-디메틸-4,4′-디페닐메탄디이소시아네이트, 1,6-헥산디이소시아네이트, 4,4′-바이페닐렌디이소시아네이트, 3,3′-디메틸페닐렌디이소시아네이트, p-페닐렌디이소시아네이트, m-페닐렌디이소시아네이트, 1,5-나프탈렌디이소시아네이트, 1,4-자일렌디이소시아네이트, 1,3-자일렌디이소시아네이트 등을 사용할 수 있으며 바람직하게는 2,4-톨루엔디이소시아네이트 및 그 이성질체, p-페닐렌디이소시아네이트, 이소포론디이소시아네이트, 헥사메틸렌디이소시아네이트를 사용하는 편이 좋다. 폴리에테르폴리올류로는 분자내에 2개 이상의 수산기를 갖고 분자량이 1,000∼4,000인 폴리프로필렌글리콜과 분자내에 3개 이상의 수산기를 갖고 분자량이 3,000∼6,000인 에틸렌옥사이드/프로필렌옥사이드 랜덤 공중합체를 단독 또는 혼합하여 사용한다. 바람직하게는 분자내에 3개의 수산기를 갖고 분자량이 3,000∼6,000인 에틸렌옥사이드/프로필렌옥사이드 랜덤 공중합체를 단독으로 사용하는 편이 좋다.In preparing a polyurethane prepolymer, 0.15 to 0.5 moles of one or more polyether polyols are added to 1 to 3 moles of diisocyanate, and isophorone diisocyanate, 2,4-toluene diisocyanate and its isomers and diphenyl are used as diisocyanates. Methane diisocyanate, hexamethylene diisocyanate, lysine diisocyanate, trimethylhexamethylene diisocyanate, 2,2-bis-4'-propane isocyanate, 6-isopropyl-1,3-phenyldiisocyanate, bis (2-isocyanate ethyl ) -Fumarate, 3,3'-dimethyl-4,4'-diphenylmethane diisocyanate, 1,6-hexanediisocyanate, 4,4'-biphenylene diisocyanate, 3,3'-dimethylphenylene diisocyanate , p-phenylenedi isocyanate, m-phenylenedi isocyanate, 1,5-naphthalenedi isocyanate, 1,4-xylene diisocyanate, 1,3-xylene diisocyanate Socyanate etc. can be used, Preferably 2, 4- toluene diisocyanate and its isomer, p-phenylene diisocyanate, isophorone diisocyanate, and hexamethylene diisocyanate are preferable. As polyether polyols, a single or mixed polypropylene glycol having two or more hydroxyl groups in a molecule having a molecular weight of 1,000 to 4,000 and an ethylene oxide / propylene oxide random copolymer having a molecular weight of 3,000 to 6,000 having three or more hydroxyl groups in a molecule Use it. Preferably, an ethylene oxide / propylene oxide random copolymer having three hydroxyl groups in a molecule and having a molecular weight of 3,000 to 6,000 is preferably used alone.
발포제는 물리적 발포제로써 클로로플루오로카본(CFC-141b), 메틸렌클로라이드(Methylene chloride), 화학적 발포제로써 증류수를 사용할 수 있으며 바람직하게는 증류수를 사용하는 편이 좋다.The blowing agent may be chlorofluorocarbon (CFC-141b), methylene chloride (Methylene chloride) as a physical blowing agent, distilled water may be used as a chemical blowing agent, preferably distilled water.
가교제는 보조약제 역할을 하는 것으로 분자내에 2개 이상의 수산기를 갖는 1,3-부탄디올, 1,4-부탄디올, 1,5-펜탄디올, 1,6-헥산디올, 네오펜틸글리콜, 프로필렌글리콜, 에틸렌글리콜, 분자량이 200∼2000인 폴리에틸렌글리콜, 글레세롤, 트리메틸올에탄, 트리메틸올프로판, 펜타에리트리톨(pentaerythritol), 솔보스(sorbose), 솔비톨(sorbitol)등을 단독 또는 혼합하여 사용할 수 있으며 바람직하게는 글리세롤, 솔비톨, 분자량이 200∼2000인 폴리에틸렌글리콜, 트리메틸올프로판을 사용하는 편이 좋다.The crosslinking agent acts as an auxiliary agent, and has 1,3-butanediol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, neopentylglycol, propylene glycol, and ethylene having two or more hydroxyl groups in a molecule. Glycol, polyethylene glycol having a molecular weight of 200 to 2000, glycol, trimethylol ethane, trimethylolpropane, pentaerythritol, sorbose, sorbitol, and the like can be used alone or in combination. Preferably, glycerol, sorbitol, polyethylene glycol having a molecular weight of 200 to 2000, and trimethylol propane may be used.
첨가제로서 계면활성제는 폴리우레탄 폼 드레싱재의 셀 사이즈(cell size)를 조절하는 역할을 하는 것으로, 에틸렌옥사이드-프로필렌옥사이드 블록 공중합체로서 독일 바스프사의 L-62, F-68, F-127, F-108 또는 실리콘계 계면활성제로서 Osi사의 L-5305, L-5302, L-3150을 사용할 수 있고, 보습제 및 상처치유 촉진제로서는 히아루론산, 알지네이트, 펙틴, 잔탄검, 구아검, 카라야검, 소디움 카르복시메틸셀룰로스, 콘드로이틴설페이트, 3-아미노프로필디하이드로젠 포스페이트, 키토마린 등을 사용할 수 있다.As an additive, the surfactant plays a role in controlling the cell size of the polyurethane foam dressing material. As an ethylene oxide-propylene oxide block copolymer, L-62, F-68, F-127, and F- of BASF, Germany 108 or a silicone-based surfactant can be used O-5 L-5305, L-5302, L-3150, and as a moisturizer and wound healing accelerator, hyaluronic acid, alginate, pectin, xanthan gum, guar gum, karaya gum, sodium carboxymethylcellulose, Chondroitin sulfate, 3-aminopropyldihydrogen phosphate, chitomarin and the like can be used.
이하 본 발명을 합성예, 실시예, 비교예에 의하여 설명하나 이들은 본 발명을 상세히 설명하기 위해 제공되는 것일 뿐 이들에 의해 본 발명의 기술적 범위가 한정되는 것은 아니다.Hereinafter, the present invention will be described by synthesis examples, examples, and comparative examples, but these are merely provided to explain the present invention in detail, and the technical scope of the present invention is not limited thereto.
[합성예 1]Synthesis Example 1
이소시아네이트 말단기를 갖는 폴리우레탄 프레폴리머의 제조는 교반기가 달린 3리터 둥근바닥 플라스크를 이용하여 335g의 디페닐메탄디이소시아네이트를 투입하고 60℃로 승온한 후 3개의 수산기를 갖고 에틸렌옥사이드/프로필렌옥사이드 랜덤 공중합체이며 에틸렌옥사이드 함량이 75%인 것(한국폴리올사의 TR-705) 1665g을 소량씩 첨가하면서 이론 NCO%에 도달할 때까지 7시간 동안 반응시켜 제조하였다. 반응 중간에 시료를 채취하여 NCO%를 측정하였고 NCO%는 n-뷰틸아민 표준 용액을 사용하여 적정법에 의해 측정하였다.Polyurethane prepolymers having isocyanate end groups were prepared by adding 335 g of diphenylmethane diisocyanate using a 3-liter round bottom flask equipped with a stirrer and heating to 60 ° C., followed by three hydroxyl groups. It was prepared by reacting for 7 hours until reaching the theoretical NCO% while adding a small amount of 1665g of copolymer and 75% of ethylene oxide (TR-705 of Polyol Korea). Samples were taken in the middle of the reaction to determine NCO% and NCO% was determined by titrimetry using n-butylamine standard solution.
[합성예 2]Synthesis Example 2
교반기가 달린 3리터 둥근바닥 플라스크를 이용하여 454g의 디페닐메탄디이소시아네이트를 투입하고 60℃로 승온한 후 3개의 수산기를 갖고 에틸렌옥사이드/프로필렌옥사이드 랜덤 공중합체이며 에틸렌옥사이드 함량이 75%인 것(한국폴리올사의 TR-705) 1546g을 소량씩 첨가하면서 이론 NCO%에 도달할 때까지 7시간 동안 반응시켜 제조하였다. 반응 중간에 시료를 채취하여 NCO%를 측정하였고 NCO%는 n-뷰틸아민 표준 용액을 사용하여 적정법에 의해 측정하였다.454 g of diphenylmethane diisocyanate was added to a 3 liter round bottom flask equipped with a stirrer, and heated to 60 ° C., followed by three hydroxyl groups. 1546 g of TR-705 (Korea Polyol Co., Ltd.) was added in small portions, and reacted for 7 hours until the theoretical NCO% was reached. Samples were taken in the middle of the reaction to determine NCO% and NCO% was determined by titrimetry using n-butylamine standard solution.
[합성예 3]Synthesis Example 3
교반기가 달린 3리터 둥근바닥 플라스크에 347g의 디페닐메탄디이소시아네이트를 투입하고 60℃로 승온한 후 3개의 수산기를 갖고 폴리프로필렌글리콜(한국폴리올사의 GP-3000) 338g과 에틸렌옥사이드/프로필렌옥사이드 랜덤 공중합체이며 에틸렌옥사이드 함량이 75%인 것(한국폴리올사의 TR-705) 1315g을 소량씩 첨가하면서 이론 NCO%에 도달할 때까지 7시간 동안 반응시켜 제조하였다. 반응 중간에 시료를 채취하여 NCO%를 측정하였고 NCO%는 n-뷰틸아민 표준 용액을 사용하여 적정법에 의해 측정하였다.347 g of diphenylmethane diisocyanate was added to a 3 liter round bottom flask equipped with a stirrer, and the temperature was raised to 60 ° C., followed by three hydroxyl groups, 338 g of polypropylene glycol (GP-3000, Polyol Korea Co., Ltd.) and ethylene oxide / propylene oxide random air. It was prepared by reacting for 7 hours until the theoretical NCO% was reached while adding 1315 g of the compound, which had a ethylene oxide content of 75% (TR-705 of Polyol Korea) in small amounts. Samples were taken in the middle of the reaction to determine NCO% and NCO% was determined by titrimetry using n-butylamine standard solution.
[실시예 1]Example 1
친수성 폴리우레탄 폼 드레싱재는 상기 합성예 1에서 제조한 폴리우레탄 프레폴리머 60중량%에 증류수 24중량%, 글리세린 13중량%, 첨가제로써 F-127(바스프사) 2.5중량%, STARTEX 201 Yellow(송원칼라) 0.5중량%를 첨가하여 3,000∼5,000rpm으로 5초 동안 교반한 후 일정한 형상의 몰드에 주입하여 발포 제조하였다. 이 때 금형의 온도는 30∼50℃로 하고 주입 후 10∼15분후에 개폐 탈형하였다.The hydrophilic polyurethane foam dressing material is 60% by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 24% by weight of distilled water, 13% by weight of glycerin, 2.5% by weight of F-127 (BASF) as an additive, STARTEX 201 Yellow (Songwon Color) ) 0.5 wt% was added and stirred at 3,000 to 5,000 rpm for 5 seconds, and then injected into a mold of a predetermined shape to prepare a foam. At this time, the temperature of the mold was set to 30 to 50 ° C, and the mold was opened and closed for demolding 10 to 15 minutes after the injection.
얻어진 친수성 폴리우레탄 폼 드레싱재는 아래와 같은 방법으로 물성을 측정하였으며, 그 결과을 다음 표1에 나타내었다.The obtained hydrophilic polyurethane foam dressing material was measured by the following method, the results are shown in Table 1 below.
① 기계적물성(인장강도, 신율, 모듈러스)① Mechanical Properties (tensile strength, elongation, modulus)
인장시험기(Universal Test Machine, USA, Instron)로 JIS-K-6401에 의거하여 측정하였다.It measured by the tensile tester (Universal Test Machine, USA, Instron) based on JIS-K-6401.
② 흡수도%② Absorbance%
친수성 폴리우레탄 폼 드레싱재를 3Cm×3Cm의 크기로 취하여 70℃ oven에서 24시간 동안 drying시킨 후 초기 무게(A)를 측정하고 25℃ 증류수에 48시간 동안 함침 보관한 후 꺼내어 무진 휴지로 표면의 물기를 닦아낸 후 무게(B)를 측정하였다. 최종적으로 다음 식을 이용하여 계산하였다.Take the hydrophilic polyurethane foam dressing material in the size of 3Cm × 3Cm and dry it in the 70 ℃ oven for 24 hours, measure the initial weight (A), impregnate it in distilled water at 25 ℃ for 48 hours, take it out and drain the surface with dust-free tissue. After wiping off the weight (B) was measured. Finally, the following equation was used.
흡수도% = (B-A)/A ×100Absorbance% = (B-A) / A × 100
③ 투습도③ moisture permeability
항온 항습 장치를 이용하여 KS M 6886의 시험방법에 의거하여 측정하였다. 이 때 온도는 40℃로 하였고, 상대 습도는 90%로 하였으며 다음식에 따라 투습도를 계산하였다.It was measured according to the test method of KS M 6886 using a constant temperature and humidity device. At this time, the temperature was 40 ° C, the relative humidity was 90%, and the moisture permeability was calculated according to the following equation.
P=A/SP = A / S
A=((a1-a0) +(a2-a1)+(a3-a2))/3A = ((a 1 -a 0 ) + (a 2 -a 1 ) + (a 3 -a 2 )) / 3
여기에서, P : 투습도(g/m2/24hr)Here, P: moisture vapor permeability (g / m 2 / 24hr)
A : 1시간의 평균 증가량(g)A: average amount of increase per hour (g)
S : 시험편의 투습 면적(m2)S: moisture permeation area of the test piece (m 2 )
④ 셀 사이즈(Cell size)④ Cell size
주사전자현미경을 사용하여 친수성 폴리우레탄 폼 드레싱재의 표면과 단면의 셀 사이즈(Cell size)를 측정하였다.The cell size of the surface and the cross section of the hydrophilic polyurethane foam dressing material was measured using a scanning electron microscope.
⑤ 세포에 대한 독성 실험⑤ Toxicity test on cells
친수성 폴리우레탄 폼 드레싱재의 세포에 대한 독성을 평가하기 위하여 IS0 10993-5를 이용하였다. 세포는 국립위생연구소에서 제공한 마우스 섬유아세포인 3T3 세포를 이용하였다. 12 Well 플라스틱 배양 접시에 10% FCS(Fetal Calf Serum)를 함유하는 RPMI-1640(Roswell Park Memorial Institute-1640)을 배양액으로 하여 3T3 세포를 2 ×104/㎠로 파종시켰으며 37℃, 5% CO2하에서 4일 동안 2차 배양하였다. 여기에 친수성 폴리우레탄 폼 드레싱재를 직접적으로 접촉시켜 각각 1일, 3일 동안 배양시켜 트립신/EDTA(Ethylene Diamine Tetraacetic Acid) 용액을 사용하여 수확한 후 0.4% 트립판 블루 용액으로 염색하여 살아있는 세포의 수를 헤마싸이토미터로 측정하였다.IS0 10993-5 was used to evaluate the toxicity of the hydrophilic polyurethane foam dressings to the cells. Cells were used 3T3 cells, mouse fibroblasts provided by the National Institute of Sanitation. 3T3 cells were seeded at 2 × 10 4 / cm 2 using RPMI-1640 (Roswell Park Memorial Institute-1640) containing 10% FCS (Fetal Calf Serum) in a 12 well plastic culture dish. Secondary incubation for 4 days under CO 2 . The hydrophilic polyurethane foam dressing material was directly contacted and incubated for 1 day and 3 days, respectively, harvested using trypsin / EDTA (Ethylene Diamine Tetraacetic Acid) solution, and stained with 0.4% trypan blue solution. The number was measured with a hemasitometer.
⑥ 상처치유효과의 측정⑥ Measurement of wound healing effect
친수성 폴리우레탄 폼 드레싱재의 상처치유 효과를 관찰하기 위하여 연령은 평균 5주, 몸무게는 25∼30g의 Rat을 이용하였다. Rat은 에테르로 흡인 마취시킨 후 등부위에 직경 6∼30mm의 2개의 피부결손을 만들고 한쪽은 드레싱을 실시하였고 다른쪽은 대조군으로 드레싱하지 않았다. 드레싱후 3일, 6일, 9일째 시간 경과에 따른 피부결손부위의 크기 변화 및 조직세포의 탈리현상 등을 관찰하였다.In order to observe the wound healing effect of the hydrophilic polyurethane foam dressing material, an average age of 5 weeks and a weight of 25-30 g were used. Rats were anesthetized with ether, and two skin defects of 6-30 mm in diameter were made on the back and one was dressed and the other was not dressed as a control. At 3, 6, and 9 days after dressing, changes in the size of skin defects and detachment of tissue cells were observed.
[실시예 2]Example 2
친수성 폴리우레탄 폼 드레싱재는 상기 합성예 1에서 제조한 폴리우레탄 프레폴리머 53중량%에 증류수 24중량%, 글리세린 19중량%, F-127 2.5중량%, 히아루론산 1.0중량%, STARTEX 201 Yellow 0.5중량%를 첨가하여 3000∼5,000rpm으로 5초 동안 교반한 후 일정한 형상의 몰드에 주입하여 발포 제조하였다. 이 때 금형의 온도는 30∼50℃로 하고 주입 후 10∼15분후에 개폐 탈형하였다. 물성은 실시예 1에 예시된 방법에 의해 측정하였으며, 그 결과를 다음 표1에 나타내었다.Hydrophilic polyurethane foam dressing material is a polyurethane prepolymer prepared in Synthesis Example 1 53% by weight of distilled water 24% by weight, glycerin 19% by weight, F-127 2.5% by weight, hyaluronic acid 1.0% by weight, STARTEX 201 Yellow 0.5% by weight After the addition was stirred for 5 seconds at 3000 ~ 5,000rpm and injected into a mold of a predetermined shape to prepare a foam. At this time, the temperature of the mold was set to 30 to 50 ° C, and the mold was opened and closed for demolding 10 to 15 minutes after the injection. Physical properties were measured by the method illustrated in Example 1, and the results are shown in Table 1 below.
[실시예 3]Example 3
친수성 폴리우레탄 폼 드레싱재는 상기 합성예 1에서 제조한 폴리우레탄 프레폴리머 57중량%에 증류수 26중량%, 글리세린 13.5중량%, F-127 2.9중량%, 실버설퍼다이아진(Silver Sulfadiazine) 0.1중량%, STARTEX 201 Yellow 0.5중량%를 첨가하여 3,000∼5,000rpm으로 5초 동안 교반한 후 일정한 형상의 몰드에 주입하여 발포 제조하였다. 이 때 금형의 온도는 30∼50℃로 하고 주입 후 10∼15분후에 개폐 탈형하였다. 물성은 실시예 1에 예시된 방법에 의해 측정하였으며, 그 결과를 다음 표1에 나타내었다.Hydrophilic polyurethane foam dressing material is 26% by weight of distilled water, 13.5% by weight of glycerin, 2.9% by weight of F-127, 0.1% by weight of silver sulfur diazine (Silver Sulfadiazine), 57% by weight of polyurethane prepolymer prepared in Synthesis Example 1 0.5 wt% of STARTEX 201 Yellow was added thereto, stirred at 3,000 to 5,000 rpm for 5 seconds, and then foamed into a mold of a predetermined shape. At this time, the temperature of the mold was set to 30 to 50 ° C, and the mold was opened and closed for demolding 10 to 15 minutes after the injection. Physical properties were measured by the method illustrated in Example 1, and the results are shown in Table 1 below.
[실시예 4]Example 4
친수성 폴리우레탄 폼 드레싱재는 상기 합성예 2에서 제조한 폴리우레탄 프레폴리머 60중량%에 증류수 24중량%, 글리세린 13중량%, F-127 2.0중량%, 히아루론산 0.5중량%, STARTEX 201 Yellow 0.5중량%를 첨가하여 3,000∼5,000rpm으로 5초 동안 교반한 후 일정한 형상의 몰드에 주입하여 발포 제조하였다. 이 때 금형의 온도는 30∼50℃로 하고 주입 후 10∼15분후에 개폐 탈형하였다. 물성은 실시예 1에 예시된 방법에 의해 측정하였으며, 그 결과를 다음 표1에 나타내었다.Hydrophilic polyurethane foam dressing material is 24% by weight of distilled water, 13% by weight of glycerin, 2.0% by weight of F-127, 0.5% by weight of hyaluronic acid, 0.5% by weight of STARTEX 201 Yellow to 60% by weight of the polyurethane prepolymer prepared in Synthesis Example 2. After the addition was stirred for 5 seconds at 3,000 ~ 5,000rpm and injected into a mold of a predetermined shape to prepare a foam. At this time, the temperature of the mold was set to 30 to 50 ° C, and the mold was opened and closed for demolding 10 to 15 minutes after the injection. Physical properties were measured by the method illustrated in Example 1, and the results are shown in Table 1 below.
[실시예 5]Example 5
친수성 폴리우레탄 폼 드레싱재는 상기 합성예 3에서 제조한 폴리우레탄 프레폴리머 60중량%와 증류수 23중량%, 글리세린 13중량%, F-127 3.0중량%, 히아루론산 0.5중량%, STARTEX 201 Yellow 0.5중량%를 혼합하여 3,000∼5,000rpm으로 5초 동안 교반한 후 일정한 형상의 몰드에 주입하여 발포 제조하였다. 이 때 금형의 온도는 30∼50℃로 하고 주입 후 10∼15분후에 개폐 탈형하였다. 물성은 실시예 1에서 예시된 방법에 의해 측정하였으며, 그 결과를 다음 표1에 나타내었다.Hydrophilic polyurethane foam dressing material is 60% by weight of the polyurethane prepolymer prepared in Synthesis Example 3, 23% by weight of distilled water, 13% by weight of glycerin, 3.0% by weight of F-127, 0.5% by weight of hyaluronic acid, 0.5% by weight of STARTEX 201 Yellow The mixture was stirred for 5 seconds at 3,000 to 5,000 rpm and then injected into a mold of a predetermined shape to prepare a foam. At this time, the temperature of the mold was set to 30 to 50 ° C, and the mold was opened and closed for demolding 10 to 15 minutes after the injection. Physical properties were measured by the method exemplified in Example 1, and the results are shown in Table 1 below.
[비교예 1]Comparative Example 1
폴리우레탄 프레폴리머는 시판중인 S사의 제품(Allevyn)을 적용하였고, 참고로 제조방법은 다음과 같다. 교반기가 달린 3리터 둥근바닥 플라스크에 347g의 2,4-톨루엔디이소시아네이트를 투입하고 60℃로 승온한 후 3개의 수산기를 갖고 에틸렌옥사이드/프로필렌옥사이드 랜덤 공중합체(W.R.Grace&Co.사의 WRG-7000) 1315g을 소량씩 첨가하면서 이론 NCO%에 도달할 때까지 중합 반응시켰다. 반응 중간에 시료를 채취하여 NCO%를 측정하였고 NCO%는 n-뷰틸아민 표준 용액을 사용하여 적정법에 의해 측정하였다.Polyurethane prepolymer was applied to commercially available S company (Allevyn), for reference, the manufacturing method is as follows. 347 g of 2,4-toluene diisocyanate was added to a 3-liter round bottom flask equipped with a stirrer and heated to 60 ° C., followed by three hydroxyl groups. 1315 g of ethylene oxide / propylene oxide random copolymer (WRGrace & Co., Ltd. WRG-7000) Was added in small portions, and the polymerization was carried out until the theoretical NCO% was reached. Samples were taken in the middle of the reaction to determine NCO% and NCO% was determined by titrimetry using n-butylamine standard solution.
친수성 폴리우레탄 폼 드레싱재는 이상과 같이 합성한 폴리우레탄 프레폴리머 50중량%에 증류수 48중량%, F-68 2중량%를 첨가하여 3000∼5000rpm으로 고속 교반한 후 그 혼합물을 캐스팅하고 양면에 필름을 라미네이션시켜 제조하였다.Hydrophilic polyurethane foam dressing material was added to 50% by weight of the polyurethane prepolymer synthesized as described above, 48% by weight of distilled water and 2% by weight of F-68 were stirred at a high speed of 3000 to 5000rpm, and then the mixture was cast. Prepared by lamination.
물성은 실시예 1에서 예시된 방법에 의해 측정하였으며 이상의 실험 결과를 다음 표1에 나타내었다.Physical properties were measured by the method exemplified in Example 1, and the experimental results are shown in Table 1 below.
상기 표1의 실시예 1, 2, 3에서 알 수 있듯이 폴리우레탄 프레폴리머의 NCO%와 가교제인 글리세린 첨가량이 증가하면 우레탄 결합(하드세그먼트)이 많아져 기계적 물성은 증가하고 상대적으로 친수성 부분(소프트세그먼트)이 적어져 흡수도는 감소한다. 실시예 4에서는 폴리우레탄 프레폴리머 제조시 사용되는 소수성인 폴리프로필렌글리콜과 친수성인 에틸렌옥사이드/프로필렌옥사이드 랜덤 공중합체의 함량비 조절에 따라 팽윤도를 조절할 수 있음을 알 수 있다. 즉 에틸렌옥사이드/프로필렌옥사이드 랜덤 공중합체의 함량이 증가할수록 흡수도는 증가한다. 도2에서 알 수 있듯이 폴리우레탄 폼 드레싱재의 표면은 직경 3∼60㎛의 포아(pore)를 갖는 얇은 막으로 이루어져 있으며 단면은 직경 50∼500㎛의 오픈 셀(open cell) 구조의 폼으로 이루어져 있다. 이러한 구조적 특징으로부터 투습도는 기존 제품에 비해 높고 흡수 삼출물의 투습 건조에 따른 지속적인 삼출물 흡수가 가능하며 많은 양의 삼출물이 비교적 장기간 발생되는 상처에도 적용 가능하다.As can be seen in Examples 1, 2, and 3 of Table 1, when the NCO% of the polyurethane prepolymer and the amount of glycerin as a crosslinking agent are increased, the urethane bond (hard segment) increases, thereby increasing the mechanical properties and the relatively hydrophilic part (soft The number of segments) decreases and the absorbance decreases. In Example 4 it can be seen that the degree of swelling can be adjusted according to the content ratio of the hydrophobic polypropylene glycol and hydrophilic ethylene oxide / propylene oxide random copolymer used in preparing the polyurethane prepolymer. That is, as the content of the ethylene oxide / propylene oxide random copolymer increases, the absorbency increases. As can be seen in Figure 2, the surface of the polyurethane foam dressing material is made of a thin film having a pore (pore) of 3 ~ 60㎛ diameter and the cross section is composed of a foam of open cell (open cell) structure of 50 ~ 500㎛ diameter . From this structural feature, the moisture permeability is higher than that of the existing products, and it is possible to continuously absorb the exudates due to the moisture-permeable drying of the absorbent exudates, and it is also applicable to wounds in which a large amount of exudate is generated for a relatively long time.
본 발명의 친수성 플리우레탄 폼 드레싱재(실시예 1)는 살아있는 cell 수가 1일, 3일 경과 후 control의 cell 수에 대해 각각 7%, 30% 감소하였고 비교예 1에 비하여 탁월한 생존율을 나타내었다. 또한 동물실험 결과 무처치군(control)과 기존 제품은 상처 치유가 수축에 의해 진행되었고 가피(crust)가 형성되었으나, 본 발명의 친수성 폴리우레탄 폼 드레싱재는 재상피화에 의해 상처치유가 진행되었고 가피가 형성되지 않았다.The hydrophilic polyurethane foam dressing material (Example 1) of the present invention showed that the number of living cells decreased by 7% and 30% for the control cell number after 1 day and 3 days, respectively, and showed excellent survival rate compared to Comparative Example 1. In addition, as a result of animal experiments, the control and the existing products were wound healing progressed by shrinkage and crust was formed, but the hydrophilic polyurethane foam dressing material of the present invention was wound healing progressed by re-epithelialization Not formed.
상기 표1에서 알 수 있듯이 폴리우레탄 프레폴리머의 NCO%와 각종 원료의 첨가량을 조절함으로써 폴리우레탄 폼 자체의 물성 즉, 인장강도, 신율, 모듈러스, 흡수도, 투습도, 셀 사이즈(cell size) 등을 조절할 수 있고, 삼출물이 적은 창상으로부터 많은 창상에 이르기까지 폭넓게 사용 가능한 폴리우레탄 폼 드레싱재를 제조할 수 있다. 본 발명의 폐쇄성 드레싱재의 친수성 폴리우레탄 폼의 구조는 직경 3∼60㎛의 포아 사이즈(pore size)를 갖는 박필름 형태의 표피층(1)과 직경 50∼500㎛의 오픈(open cell) 구조의 폼 형태의 내부층(2)으로 이루어져 있다. 이러한 구조로부터, 외부로부터의 박테리아 침입을 방지하고 상처면에서의 재생세포가 드레싱재 면에 부착하지 못하게 함으로써 드레싱재 교환시 부착에 따른 환자의 고통을 방지할 수 있다. 그리고 폴리우레탄 폼에 박필름을 라미네이션시켜 제조하는 기존의 드레싱재 제조 방법 대신에 몰드발포성형법에 의해 폼 자체에 박필름을 동시에 형성시키는 드레싱재의 제조공정으로 단순화시켰다. 또한 본 발명의 친수성 폴리우레탄 폼 드레싱재에는 계면활성제, 보습제, 상처치유촉진제, 항균제 등을 포함하고 있어 상처면을 청결히 하고 재생세포의 성장을 촉진시킴으로써 치유속도를 빠르게 한다. 또한 공기투과성과 습기투과성이 모두 우수하여 많은 양의 삼출물이 비교적 장기간 발생되는 상처에도 적용가능하고 상처분비물의 지속적인 흡수가 가능하다.As can be seen from Table 1 above, by adjusting the amount of NCO% and various raw materials of the polyurethane prepolymer, the physical properties of the polyurethane foam itself, that is, tensile strength, elongation, modulus, water absorption, moisture permeability, and cell size, etc. It is possible to produce polyurethane foam dressings which can be adjusted and are widely used from wounds with few exudates to many wounds. The hydrophilic polyurethane foam of the closed dressing material of the present invention has a thin film-like skin layer 1 having a pore size of 3 to 60 µm in diameter and an open cell structure of 50 to 500 µm in diameter. It consists of an inner layer 2 of the form. From this structure, it is possible to prevent bacterial invasion from the outside and prevent regeneration cells on the wound surface from adhering to the dressing material surface, thereby preventing the pain of the patient due to the attachment during dressing material exchange. And instead of the conventional manufacturing method of manufacturing the dressing material by laminating the thin film on the polyurethane foam, it was simplified to the manufacturing process of the dressing material to simultaneously form the thin film on the foam itself by the mold foam molding method. In addition, the hydrophilic polyurethane foam dressing material of the present invention contains a surfactant, a humectant, a wound healing accelerator, an antimicrobial agent, and the like to clean the wound surface and promote the growth of regenerative cells to speed up the healing rate. In addition, it is excellent in both air permeability and moisture permeability, so that a large amount of exudates can be applied to wounds that are generated for a relatively long time, and continuous absorption of wound secretions is possible.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990026417A KR100340981B1 (en) | 1999-07-01 | 1999-07-01 | Hydrophilic Polyurethane Foam Dressing and Method of Making the Same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990026417A KR100340981B1 (en) | 1999-07-01 | 1999-07-01 | Hydrophilic Polyurethane Foam Dressing and Method of Making the Same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010008533A KR20010008533A (en) | 2001-02-05 |
KR100340981B1 true KR100340981B1 (en) | 2002-06-20 |
Family
ID=19598703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990026417A KR100340981B1 (en) | 1999-07-01 | 1999-07-01 | Hydrophilic Polyurethane Foam Dressing and Method of Making the Same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100340981B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100404140B1 (en) * | 2000-12-15 | 2003-11-01 | 주식회사 바이오폴 | Multilayer Foam Dressing And Method For Manufacturing Thereof |
WO2004039421A1 (en) * | 2002-10-29 | 2004-05-13 | Biopol Co., Ltd. | Polyurethane foam dressing for wound filler and method for man ufacturing thereof |
WO2008156285A1 (en) * | 2007-06-21 | 2008-12-24 | Wonbiogen Co., Ltd. | Method for producing hydrophilic foam dressing and hydrophilic foam dressing produced thereby |
US7777091B2 (en) | 2006-12-19 | 2010-08-17 | Biopol Co., Ltd. | Polyurethane foam dressing with improved moisturization |
US20210378875A1 (en) * | 2018-10-05 | 2021-12-09 | John J. Ryan (Sealing Products) Limited | Wound contact surface and method of manufacture |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100716658B1 (en) * | 2005-11-11 | 2007-05-09 | 주식회사 원바이오젠 | The method for manufacturing and apparatus of polyurethane foam dressing |
KR100719433B1 (en) * | 2005-11-25 | 2007-05-17 | 주식회사 원바이오젠 | The method for manufacturing and apparatus of adhesive hydrophilic polyurethane film dressing |
CN113577375A (en) * | 2021-08-09 | 2021-11-02 | 南昌智产科技有限公司 | Medical sterile foam dressing and preparation method thereof |
CN116178670B (en) * | 2023-04-28 | 2023-07-28 | 山东一诺威聚氨酯股份有限公司 | Polyurethane composite material for medical dressing foam and preparation method thereof |
-
1999
- 1999-07-01 KR KR1019990026417A patent/KR100340981B1/en active IP Right Grant
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100404140B1 (en) * | 2000-12-15 | 2003-11-01 | 주식회사 바이오폴 | Multilayer Foam Dressing And Method For Manufacturing Thereof |
WO2004039421A1 (en) * | 2002-10-29 | 2004-05-13 | Biopol Co., Ltd. | Polyurethane foam dressing for wound filler and method for man ufacturing thereof |
US7777090B2 (en) | 2002-10-29 | 2010-08-17 | Biopol Co., Ltd. | Polyurethane foam dressing for wound filler and method for manufacturing thereof |
US7777091B2 (en) | 2006-12-19 | 2010-08-17 | Biopol Co., Ltd. | Polyurethane foam dressing with improved moisturization |
WO2008156285A1 (en) * | 2007-06-21 | 2008-12-24 | Wonbiogen Co., Ltd. | Method for producing hydrophilic foam dressing and hydrophilic foam dressing produced thereby |
US20210378875A1 (en) * | 2018-10-05 | 2021-12-09 | John J. Ryan (Sealing Products) Limited | Wound contact surface and method of manufacture |
Also Published As
Publication number | Publication date |
---|---|
KR20010008533A (en) | 2001-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100777908B1 (en) | Moisturizing improved polyurethane foam dressing | |
EP0584361B1 (en) | Wound covering material | |
US20040018227A1 (en) | Multilayered microporous foam dressing and method for manufacturing the same | |
KR100550807B1 (en) | Polyurethane Foam Dressing For Wound Filler And Method For Manufacturing Thereof | |
KR101787192B1 (en) | Antimicrbacterial dressing material and method for preparing thereof | |
CN108355162B (en) | Medical dressing of antibiotic hydrophilic polyurethane foam | |
KR100859339B1 (en) | Silicon composition for dressing, the dressing and the method for manufacturing it | |
KR100345034B1 (en) | Manufacturing method of dressing agent for wound healing | |
KR20190098881A (en) | Manufacturing method of polyurethane foam/ hydrofiber complex and wound dressing using polyurethane foam/ hydrofiber complex | |
KR100340981B1 (en) | Hydrophilic Polyurethane Foam Dressing and Method of Making the Same | |
CN1231192C (en) | Multilayer polyporous foam dressing material and its producing method | |
TWI733503B (en) | Polyurethane foam dressing and wound dressing products | |
KR100404140B1 (en) | Multilayer Foam Dressing And Method For Manufacturing Thereof | |
KR100359864B1 (en) | Dressing Having Microporous polyurethane film for Wound Healing | |
CN105056279A (en) | Double-layer polyurethane-based collagen-compounded dressing | |
CN111748071B (en) | Hydrophilic polyurethane foam dressing and preparation method thereof | |
KR200185721Y1 (en) | Foam type dressing with microporous skin layer | |
KR20050061195A (en) | Hydrophilic polyurethane foam dressing with double-layer structure | |
KR102269037B1 (en) | Mutifunctional medical polyurethane film having improved permeability by controlling fine porosity and method of manufacturing the same | |
KR100667292B1 (en) | Wound dressing | |
KR102182811B1 (en) | A dressing composition for protecting wound having improved moisturizing and exudation management ability | |
CN117752844A (en) | Double-sided amphiphilic composite medical dressing and preparation method thereof | |
JP2001017527A (en) | Wound dressing | |
TW201726186A (en) | Wet wound dressing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130529 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20140602 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20150602 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20160602 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20170526 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20180604 Year of fee payment: 17 |